Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 690.00 | |
5 mg | In stock | $ 1,460.00 | |
10 mg | In stock | $ 1,970.00 | |
25 mg | In stock | Inquiry | |
50 mg | 10-14 weeks | Inquiry |
Description | Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively. |
Targets&IC50 | CTL laspase-like:28 nM, CTL:3.5 nM, Trypsin like:430 nM |
In vitro |
Marizomib (60 nM; 24 h; glioma cells) causes apoptosis and caspase-3 activation in glioma cells.[1] Marizomib (0.1-10000 nM; 72 h; U-251 and D-54 cells) potently decreases survival of D-54 and U-251 cells in a dose-dependent manner (IC50s: ∼52 nM for U-251 and ∼20 nM for D-54).[1] |
In vivo | Marizomib (0.15 mg/kg; i.v.; twice a week for three weeks; CB-17 SCID-male mice) obviously reduces tumor growth and is not associated with any toxicity[3]. |
Synonyms | NPI-0052, Salinosporamide A, ML858 |
Molecular Weight | 313.78 |
Formula | C15H20ClNO4 |
CAS No. | 437742-34-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31.38 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Marizomib 437742-34-2 Proteases/Proteasome Ubiquitination Proteasome NPI-0052 Salinosporamide A NPI 0052 ML858 ML-858 NPI0052 ML 858 inhibitor inhibit